Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Autoantibodies as diagnostic biomarkers for the detection, subtyping, and progression of Multiple Sclerosis

ABSTRACT: Human serum samples from Multiple Sclerosis (MS) subjects and healthy control subjects were probed onto human protein microarrays in order to identify differentially expressed autoantibody biomarkers that could be used as diagnostic indicators. Other neurodegenerative and non-neurodegenerative diseases were also used to help measure the specificity of the selected biomarkers.

ORGANISM(S): Homo sapiens

PROVIDER: GSE95718 | GEO | 2017/07/26

SECONDARY ACCESSION(S): PRJNA378221

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Diagnosis of Early-Stage Parkinson's Disease Using Autoantibodies as Blood-based Biomarkers

Project description:Human serum samples from early-stage Parkinson's disease and non-diseased controls were probed onto human protein microarrays in order to identify differentially expressed autoantibody biomarkers that could be used as diagnostic indicators. Other neurodegenerative and non-neurodegenerative diseases were also used to help measure the specificity of the selected biomarkers.

2015-09-30 | GSE62283 | GEO

Detection of Alzheimer’s Disease at Mild Cognitive Impairment and Disease Progression Using Autoantibodies as Blood-based Biomarkers

Project description:Human serum samples from Alzheimer's disease driven mild cognitive impairment and non-diseased controls were probed onto human protein microarrays in order to identify differentially expressed autoantibody biomarkers that could be used as diagnostic indicators. Other neurodegenerative and non-neurodegenerative diseases were also used to help measure the specificity of the selected biomarkers.

2016-05-03 | GSE74763 | GEO

Diagnosis of Alzheimer's Disease Based on Disease-Specific Autoantibody Profiles

2011-07-13 | GSE29676 | GEO

Diagnosis of Parkinson's Disease Based on Disease-Specific Autoantibody Profiles

2012-02-27 | GSE29654 | GEO

Diagnosis of Parkinson's Disease Based on Disease-Specific Autoantibody Profiles

Project description:Parkinson's Disease (PD) and Non-Demented Control (NDC) human sera were probed onto human protein microarrays in order to identify differentially expressed autoantibody biomarkers that could be used as diagnostic indicators. In the study presented here, 29 PD and 40 NDC human serum samples were probed onto human protein microarrays in order to identify differentially expressed autoantibodies. Microarray data was analyzed using several statistical significance algorithms, and autoantibodies that demonstrated significant group prevelance were selected as biomarkers of disease. Prediction classification analysis tested the diagnostic efficacy of the identified biomarkers; and differentiation of PD samples from other neurodegeneratively-diseased and non-neurodegeneratively-diseased controls (Alzheimer's disease, multiple sclerosis, and breast cancer) confirmed their specificity.

2012-02-27 | E-GEOD-29654 | biostudies-arrayexpress

Diagnosis of Alzheimer's Disease Based on Disease-Specific Autoantibody Profiles

Project description:Alzheimer's Disease (AD) and Non-Demented Control (NDC) human sera were probed onto human protein microarrays in order to identify differentially expressed autoantibody biomarkers that could be used as diagnostic indicators. In the study presented here, 50 AD and 40 NDC human serum samples were probed onto human protein microarrays in order to identify differentially expressed autoantibodies. Microarray data was analyzed using several statistical significance algorithms, and autoantibodies that demonstrated significant group prevelance were selected as biomarkers of disease. Prediction classification analysis tested the diagnostic efficacy of the identified biomarkers; and differentiation of AD samples from other neurodegeneratively-diseased and non-neurodegeneratively-diseased controls (Parkinson's disease and breast cancer, respectively) confirmed their specificity.

2011-07-12 | E-GEOD-29676 | biostudies-arrayexpress

Detection of early-stage Alzheimer’s pathology using blood-based autoantibody biomarkers in elderly hip fracture repair patients

Project description:Human plasma samples from CDR = 0 and CDR ≥ 0.5 patients, and serum samples from non-diseased, non-surgical controls were probed onto human protein microarrays to test the utility of a previously established panel of MCI-specific autoantibody (aAB) biomarkers to detect prodromal AD presurgically in individuals admitted into the hospital for hip fracture repair (HFR) surgery.

2020-04-14 | GSE137422 | GEO

Identification of autoantibodies in colorectal cancer

Project description:Colorectal cancer remains the leading cause of cancer death worldwide. The 5-year annual survival is less than half of the incidence rate that is predominantly due to late diagnosis of the disease striking the very urgent clinical necessity for biomarkers capable of detecting cancer malignancy at an early onset. During neoplastic transformation, cells undergo several behavioral changes that subsequently result in defects in cell division, immune tolerance, inflammation, and cellular death mechanisms. These processes lead to the development of tumor antigens (TA) that evoke an immune response and subsequent generation of antibodies against self-proteins, called autoantibodies (AAbs). This study aims to identify autoantibody biomarkers in patient’s sera for early screening of the cancer. High-density human proteome array having approximately 17,000 full-length recombinant human proteins were used in the study. The generation of an autoimmune response against important cancer-linked pathways could be important in terms of screening for the disease. The process of immune surveillance starts as tumorigenesis begins and hence autoantibodies can be detected in a very early stage of cancer. Moreover, AAbs can be easily extracted from blood serum through the least invasive test for disease screening.

2022-12-07 | E-MTAB-12081 | biostudies-arrayexpress

Genome-wide expression kinetics of children with T1D-associated autoantibodies compared to healthy matched controls I

Project description:To unravel genes and molecular pathways involved in the pathogenesis of type 1 diabetes (T1D), we performed genome-wide gene expression profiling of prospective venous blood samples from children developing T1D-associated autoantibodies or progressing towards clinical diagnosis. 63 peripheral blood RNA samples from 6 autoantibody-positive children (Case) and their matched controls (Control) were analyzed with Illumina Sentrix WG-6 v2 genome-wide arrays, in order to study the gene expression changes occuring during the pathogenesis of Type 1 diabetes (T1D). Each case child (positive for T1D-specific autoantibodies) was matched with a persistently autoantibody-negative control child, with the same HLA-DQB1 risk category, gender, and place and date of birth. Seroconversion is determined as the first detection of T1D-specific autoantibody/autoantibodies (ICA titre >4 JDFU, IAA >3.47 RU, GADA >5.4 RU, IA-2A >0.43 RU, ZnT8A >0.61 RU).

2014-02-20 | E-GEOD-30208 | biostudies-arrayexpress

Genome-wide expression kinetics of children with T1D-associated autoantibodies compared to healthy matched controls II

Project description:To unravel genes and molecular pathways involved in the pathogenesis of type 1 diabetes (T1D), we performed genome-wide gene expression profiling of prospective venous blood samples from children developing T1D-associated autoantibodies or progressing towards clinical diagnosis. 58 peripheral blood RNA samples from 4 autoantibody-positive children and their matched controls were analyzed with Illumina Sentrix WG-6 v2 genome-wide arrays, in order to study the gene expression changes occuring during the pathogenesis of Type 1 diabetes (T1D). Each case child (positive for T1D-specific autoantibodies) was matched with a persistently autoantibody-negative control child, with the same HLA-DQB1 risk category, gender, and place and date of birth. Seroconversion is determined as the first detection of T1D-specific autoantibody/autoantibodies (ICA titre >4 JDFU, IAA >3.47 RU, GADA >5.4 RU, IA-2A >0.43 RU, ZnT8A >0.61 RU).

2014-02-20 | E-GEOD-30209 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data